Κατεύθυνση Καρκίνος Πνεύμονα: Σύγχρονη Κλινικοεργαστηριακή Προσέγγιση και Έρευνα
Library of the School of Health Sciences

2020-09-02

2020

Spiliopoulou Vasiliki

Κωνσταντίνος Συρίγος, Καθηγητής, Ιατρική Σχολή, ΕΚΠΑ
Πέτρος Μπακάκος Αναπληρωτής Καθηγητής, Ιατρική Σχολή, ΕΚΠΑ
Ελένη Γκόγκα Καθηγήτρια, Ιατρική Σχολή, ΕΚΠΑ

Θεραπεία διασώσεως μετά τη χορήγηση 2ης γραμμής θεραπείας πριν και μετά την ανοσοθεραπεία στον μη μικροκυτταρικό καρκίνο πνεύμονα

Greek

Θεραπεία διασώσεως μετά τη χορήγηση 2ης γραμμής θεραπείας πριν και μετά την ανοσοθεραπεία στον μη μικροκυτταρικό καρκίνο πνεύμονα

INTRODUCTION Immunotherapy seems to be an effective treatment for patients who suffer from non-small cell lung cancer (NSCLC). In particular, the suppression of the programmed cell death axis of protein-1 and its binder established huge and prolonged responses. As a result, these inhibitors have been approved for use as a second-line and first-line treatment in patients with advanced NSCLC. In the present study, data were compared to find the appropriate rescue treatment before and after the introduction of immunotherapy in the NSCLC. METHOD Collection of samples was performed by reviewing individual patient files. The sample consisted of 108 patients, 88 men and 20 women and compared the rescue treatments they received. Comparison fields were the overall survival of patients, the deterioration time from the last line of treatment and their quality of life. RESULTS The survival of the majority of the sample from the last treatment was 5 months, ie 29 patients, at a rate of 26.9%. 11 of the patients in our sample, ie 10.2%, continue their treatment to date. The symptoms of "shortness of breath, cough, pain" appear in the largest percentage of the sample, ie 21%. The majority of the sample worsened 2 months after the last treatment, ie 43 of the 108 individuals, at a rate of 39.8%. CONCLUSIONS Immunotherapy has emerged as an important treatment option for patients with advanced NSCLC. The identification of biomarkers in order to find
6
"targeted patients" is the goal that will lead to individualized therapeutic approaches. In addition, follow-up treatment based on the above indicators will further contribute to the early detection of treatment failure and the underlying causes of ineffectiveness, in order to allow alternative follow-up treatments. Further research is needed and it is almost sure that the future belongs to immunotherapy.

Health Sciences

Lung cancer, Immunotherapy, Non small cell, Rescue therapy

No

0

No

66

158

File access is restricted only to the intranet of UoA.

https://pergamos.lib.uoa.gr/uoa/dl/object/2921807